Here, we found that the presence of Siglec-9 defined a subset of cytotoxic NK cells with a mature phenotype and enhanced chemotactic potential. Interestingly, this Siglec-9 + NK cell population was reduced in the peripheral blood of cancer patients. Broad analysis of primary tumor samples revealed that ligands of Siglec-7 and -9 were expressed on human cancer cells of different histological types. Expression of Siglec-7 and -9 ligands was associated with susceptibility of NK cell-sensitive tumor cells and, unexpectedly, of presumably NK cell-resistant tumor cells to NK cellmediated cytotoxicity. Together, these observations have direct implications for NK cell-based therapies and highlight the requirement to consider both MHC class I haplotype and tumor-specific glycosylation.
Introduction
Upon malignant transformation, sialic acid-containing carbohydrates (sialoglycans) can be aberrantly expressed by tumor cells as a result of genetic or epigenetic dysregulation of glycan synthesis pathways (e.g., glycosyltransferases) (1) (2) (3) (4) . Distinctly glycosylated tumor antigens on the cell surface or on secreted molecules (e.g., mucins) are diagnostically exploited as tumor markers (e.g., CA125, MUC1, CEA, and CA19-9). Sialoglycans influence many critical steps in tumor biology, including immunoediting, tumor growth and proliferation, invasion, metastasis, and angiogenesis; in some instances, their presence has been correlated with poor patient survival (1, 2, (5) (6) (7) (8) .
NK cells act as first line of defense in tumor immunosurveillance (9) . Distinct sialoglycan determinants are recognized as ligands to sialic acid-binding Ig-like lectin-7 (Siglec-7; also known as p75/AIRM1) and Siglec-9 receptors on human NK cells (10) , which -similar to the classical inhibitory receptors CD94/NKG2A, killer Ig-like receptors (KIRs), and Ig-like transcripts (ILTs) -contain 1 or more immunoreceptor tyrosine-based inhibition motifs (ITIMs) in their cytoplasmic tail (11, 12) . Recognition of MHC class I by inhibitory NK cell receptors provided the molecular basis of the "missing-self" hypothesis to explain the rejection of stressed, transformed, or infected cells that lack or downregulate cognate MHC class I molecules, and the associated capacity of NK cells to dis-criminate between healthy self and target cells (13, 14) . While in recent years, significant novel insights have accumulated on the role of MHC class I-specific inhibitory receptors in NK cell biology and tumor immunology (most notably in allogeneic hematopoietic stem cell transplantation for hematologic malignancies; ref. 9 ), comparably less is known about the role of MHC class I-independent ITIM-bearing receptors. Protection of tumor cells from innate immune attack can result from aberrant expression of sialoglycan ligands that engage the MHC class I-independent Siglec-7 and -9 receptors to govern NK cell inhibition.
NK cell subsets of humans consist of CD56 dim NK cells (CD56 dim CD16 + KIR + ), which represent about 90% of peripheral blood and spleen NK cells, express perforin and granzymes, and are the major cytotoxic subset (15, 16) , and CD56 bright NK cells (CD56 bright CD16 dim/-KIR -), which constitute the majority of NK cells in lymph nodes and tonsils and, upon activation, primarily respond with cytokine production (17) . Whereas Siglec-7 is known as a pan-NK cell marker (18, 19) , Siglec-9 was recently reported to be selectively expressed in a subset of CD56 dim NK cells (20) .
Siglecs comprise a lectin family of surface receptors that bind to sialoglycans and are predominantly expressed on cells of the hematopoietic system in a manner dependent on cell type and differentiation (21) (22) (23) (24) . Whereas sialic acid is ubiquitously expressed, typically at the terminal position of glycoproteins and -lipids, only very specific, distinct sialoglycan structures are recognized by individual Siglec receptors, depending on identity and linkage to subterminal carbohydrate moieties (22, 24) . Knowledge about Siglec expression and function on NK cell subsets is still limited in terms of NK cell differentiation and maturation, and the role of Siglec ligand-receptor interactions in disease remains to be explored. Whether Siglec-7 and -9 ligands in human cancer are expressed on malignant or healthy cells is a subject of controversy (3, (25) (26) (27) (28) , as is the related question as to whether absence of inhibitory Siglecligand interactions promotes or inhibits tumor progression, either by uncoupled immune stimulation or by inhibition of immune defense (10, (25) (26) (27) . Here, we found that Siglec-7 and -9 ligands were significantly overexpressed on a broad range of human malignant cells of different histological types and that surface Siglec-7 and -9 ligand expression determined cytotoxicity of human primary NK cells against both NK cell-susceptible and -resistant tumor cells. Given that Siglec-7 and -9, in analogy to KIRs, exist in humans but not in rodents (22) , we performed in vivo experiments in mice with a reconstituted human NK cell compartment. Further in-depth analysis revealed that CD56 dim Siglec-9 + NK cells exhibited a more mature phenotype with distinct functional properties, such as enhanced chemotactic potential, and that the frequency of this subset was significantly reduced in the peripheral blood of cancer patients.
Results
Siglec-7 and -9 ligands are widely expressed on tumor cells of different histological origins. To determine the extent to which tumors express Siglec-7 and -9 ligands, we directly probed tumor cells and tissue sections using recombinant chimeras of Siglec molecules fused to human IgG1 Fc domains, as this strategy takes into account the spatial and complex cellular organization of sialoglycan ligands (29) . High expression of Siglec-7 ligands was detected by flow cytometry on numerous cell lines, including HeLa cells and various leukemic (e.g., K562) and melanoma (e.g., A375) cells ( Figure 1A) . Staining for Siglec-9 ligands revealed an even broader expression profile, as high fluorescence signal intensities were detectable in the majority of tested cell lines, notably in those originating from hematologic malignancies and melanoma. In contrast to their malignant counterparts, Siglec-7 and -9 ligand expression in human PBMCs or primary melanocytes was low or undetectable ( Figure 1A ). Staining by a recombinant CD33-Fc fusion molecule was consistently negative in the tested cell lines (data not shown and Supplemental Figure 1A ; supplemental material available online with this article; doi:10.1172/JCI65899DS1), thus excluding binding mediated by nonspecific Fc (IgG1). Confocal microscopic analysis of A375 melanoma cells revealed an intense cell surface-associated expression pattern, with only sparse intracellular staining for Siglec-7 and -9 ligands ( Figure 1B ). Binding of Siglec-7-Fc and Siglec-9-Fc fusion proteins was abrogated after enzymatic digestion of sialoglycans by neuraminidase (also known as sialidase) (30) , thus confirming the sialic acid dependency of the staining. To confirm expression of Siglec-7 and -9 ligands in human malignancies, leukemic cells from patients with acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL) were analyzed for Siglec-7 and -9 ligand expression by flow cytometry. Leukemic cells from all AML (n = 3) and CLL (n = 3) patients consistently stained highly double-positive for both Siglec-7 and -9 ligand expression ( Figure 1C and Supplemental Figure 1B ). To further confirm in situ expression of Siglec-7 and -9 ligands, immunohistochemistry on paraffin-embedded sections from human primary tumor specimens from melanoma, basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and cutaneous T cell lymphoma (CTCL) patients was performed (n = 3 each; Figure 1D ). Coexpression of Siglec-7 and -9 ligands was found in specimens from 5 of 6 melanoma patients and was restricted to malignant cells. In contrast, no Siglec-7 or -9 ligand expression was found in the analyzed BCC, SCC, and CTCL specimens. Next, the melanoma cell-restricted expression of Siglec-7 and -9 ligands was further confirmed by confocal microscopy analysis. Melan-A-positive malignant melanoma cells displayed expression of Siglec-7 and -9 ligands, whereas staining of normal tissue was not detected in epidermal or dermal layers, nor in tumor-free skin sections ( Figure 1E , Supplemental Figure 1 , C-E, and data not shown), which indicated that the expression of Siglec-7 and -9 ligands in skin is confined to malignant cells.
Siglec-7 and -9 ligand expression protects tumor cells from NK cell responses. Next, we assessed the requirement of sialoglycan ligands to protect from NK cell lysis in cell lines with high (e.g., K562 and HeLa) or absent (e.g., 721.221) expression of Siglec-7 and -9 surface ligands. Desialylation by neuraminidase significantly enhanced cytolysis of NK cell-susceptible K562 cells by human peripheral blood NK cells in vitro, as measured in a 51 Cr release assay ( Figure 2 , A and B). Similar results were obtained with HeLa cells ( Figure 2 , A and C), which indicated that desialylation even enhances the susceptibility of NK cell-resistant cells. In contrast, neuraminidase treatment had no effect on 721.221 cells ( Figure 2A and Supplemental Figure 2 ). Consistent with these results, significant upregulation of the degranulation marker CD107a was found on NK cells exposed to desialylated K562 or HeLa target cells, but not to Siglec-7 and -9 ligand-negative 721.221 cells ( Figure 2D ). Intracellular synthesis of the cytokines IFN-γ and TNF-α and of the chemokine macrophage inflammatory protein-1β (MIP-1β) was increased in NK cells exposed to neuraminidase-treated K562 cells ( Figure 2E and Supplemental Figure 3 ).
The sialome, defined as "total complement of sialic acid types and linkages and their modes of presentation on a particular organelle, cell, tissue, organ, or organism" (31), varies substantially among different species (22) , and no orthologs or unambiguous functional paralogs for Siglec-7 or -9 exist in rodents (21) . Therefore, we chose humanized NOD-SCID-γ c -/-(huNSG) mice with a reconstituted human NK cell compartment (32) to test the tumorprotective role of sialoglycans in vivo. Circulating NK cells of huNSG mice expressed high levels of Siglec-7 (Supplemental Figure 4 ). Peritoneal injection of tumor cells in huNSG mice resulted in recruitment of human NK cells (human NKp46 + , murine CD45 -) within hours (data not shown). Before injection, neuraminidasetreated K562 or HeLa cells were labeled with lower CFSE concentrations compared with untreated controls, which allowed for discrimination between desialylated (low signal intensity) and nondesialylated (high signal intensity) tumor cells. Siglec-7 and -9 ligands on K562 cells were not reexpressed within 24 hours of neuraminidase treatment (Supplemental Figure 5 ). Desialylated and untreated K562 or HeLa cells were simultaneously injected at a 1:1 ratio into the peritoneal cavity of poly I:C-pretreated huNSG mice (32) . Flow cytometric analysis of the peritoneal lavage as early as 12 hours after injection revealed a decrease in the total numbers of K562 and HeLa cells (29.8% and 41.8% decreases, respectively). The loss of cells was much more pronounced among desialylated tumor cells, as concomitantly a higher percentage of untreated, fully glycosylated tumor cells was recovered ( Figure 2F ).
To further substantiate a tumor-protective role of Siglec-7 and -9 ligands, we generated Fab fragments from mAbs against Siglec-7 (clone Z176) and Siglec-9 (clone E10-286) to specifically block ligandreceptor interactions. Anti-Siglec-7 and anti-Siglec-9 Fabs at 5 μg/ml led to substantially enhanced NK cell cytotoxicity against K562 and HeLa cells, but not against 721.221 cells ( Figure 3A ), the latter of which expressed neither Siglec-7 nor -9 ligands (see above). The permissive effect of anti-Siglec-7 and anti-Siglec-9 Fabs was observable at different effector/target (E/T) ratios (Figure 3 , A-C), but blocking Siglec-9 was slightly less efficient compared with blocking Siglec-7 ( Figure 3A) , consistent with the lower frequency and reduced killing capacity of CD56 dim Siglec-9 + NK cells. The combination of Fab fragments of Siglec-7 and -9 had no additive effect in potentiating NK cell cytotoxicity (Supplemental Figure 6 ), likely because both of these structurally related receptors target similar intracellular signalling pathways. We also used intact mAbs to exploit their agonistic action, which has been demonstrated in previous studies (18, 33) . NK cell cytotoxicity was inhibited by ligation of Siglec-7 and -9 by intact anti-Siglec-7 and anti-Siglec-9 mAbs (Z176 and E10-286, respectively), but not by the null clone 191240 against Siglec-9 ( Figure 3C and Supplemental Figure 7A ). Anti-Siglec-9 did not affect the cytotoxic activity of sorted CD56 dim Siglec-9 -NK cells (Supplemental Figure  7B ). Anti-Siglec-7 and, to a lesser extent, anti-Siglec-9 mAbs inhibited CD107a upregulation and IFN-γ secretion of NK cells, but had no effect on their survival or proliferation ( Siglec-9 defines a subset of mature cytotoxic CD56 dim NK cells with enhanced chemotactic potential. Next, we set out to phenotypically and functionally characterize human primary NK cells expressing Siglec-7 and -9, and eventually to identify other Siglecs involved in modulating the effector function of NK cells. Human peripheral blood NK cells were screened by flow cytometry, which demonstrated the exclusive presence of Siglec-7 and -9 on NK cell surfaces (Supplemental Figure 8A ). This observation was confirmed after neuraminidase treatment (Supplemental Figure 8A) , to remove potentially "masking" sialoglycans bound in cis on the same cell membrane (21) . Whereas Siglec-7 was ubiquitously distributed in the NK cell compartment, Siglec-9 was absent on CD56 bright NK cells, but selectively expressed on about 40%-50% of CD56 dim NK cells, 10%-20% of which was masked, as revealed by neuraminidase treatment (Supplemental Figure 8B ). Surface expression of Siglec-9 on total NK cells or fluorescence-activated cell sorted CD56 dim Siglec-9 + NK cell subsets was not influenced by exposure to the cytokines IL-2, IL-8, IL-12, IL-15, IL-18, or IL-21, alone or in combination, nor did these cytokines induce Siglec-9 expression in Siglec-9subsets (Supplemental Figure 8 , C and D, and data not shown). Upon release from the bone marrow, human immature CD56 bright NK cells may undergo differentiation to CD56 dim NK cells in the periphery, a process that is paralleled by the acquisition (e.g., increasing number of KIRs, CD57) or loss (e.g., NKG2A, CD27) of distinct and characteristic molecules (34, 35) . CD27, a molecule expressed by naive cells, was not detectable in the CD56 dim Siglec-9 + subset; inversely, markers that typically define mature cells, like CD57 and KLRG1, were significantly upregulated in CD56 dim Siglec-9 + cells compared with the CD56 dim Siglec-9subset ( Figure 4A ). Expression of the activation marker CD69 was higher on CD56 dim Siglec-9 + cells, whereas no difference in CD25 expression was observed (data not shown).
To assess the replicative history of these NK cell subsets, we measured telomere length in CD56 bright , CD56 dim Siglec-9 + , and CD56 dim Siglec-9 -NK cells isolated from the peripheral blood of 3 healthy donors using automated multicolor flow-FISH (see Methods). Consistent with being less mature, CD56 bright cells showed a trend for longer telomeres than CD56 dim NK cells (mean, 5.00 ± 0.58 kb versus 4.56 ± 0.41 kb; P = 0.220; Figure 4B ). In contrast, CD56 dim Siglec-9 + and CD56 dim Siglec-9 -NK cells had similar mean telomere lengths (4.56 ± 0.51 and 4.55 ± 0.39 kb, respectively).
Next, we used flow cytometry to compare the expression of Siglec-7 and -9 on NK cells in human cord blood and adult peripheral blood. Even without unmasking by neuraminidase treatment, cord blood CD56 bright NK cells stained consistently Siglec-7 + , whereas adult peripheral blood cells exhibited broader staining variability (Figure 4 , C and D). Expression levels of Siglec-7 and -9 were higher on cord blood CD56 dim NK cells compared with their adult counterparts, and 40% of untreated and 60% of neuraminidase-treated cells were Siglec-9 + . Upon neuraminidase treatment, about 10% of CD56 bright NK cells from cord blood were Siglec-9 + . Together, these results suggested that acquisition of Siglec-9 is an early event upon differentiation from CD56 bright to CD56 dim NK cells, while its expression is either transient or stabilized in a subset of cells reaching full maturation.
CD56 dim Siglec-9 + NK cells exhibited a significantly reduced cytotoxic capacity against K562 target cells compared with CD56 dim Siglec-9 -NK cells ( Figure 5A ), which we eventually attributed to the elevated expression of inhibitory receptors (e.g., KIRs and ILT2) found on these cells ( Figure 5, B and C) . In contrast, expression of the activating receptor NKG2D and the natural cytotoxicity receptors (NCRs) NKp46 and NKp30 was similar between the CD56 dim Siglec-9 + and CD56 dim Siglec-9 -NK cell subsets (Supplemen- tal Figure 9 ). CD56 dim Siglec-9 + NK cells exhibited higher expression of the chemokine receptors CXCR1 and CX3CR1, while the receptors CXCR3, CCR5, and CCR7 were virtually absent ( Figure 5 , E and F). Since the most striking difference between CD56 dim Siglec-9 + and CD56 dim Siglec-9 -NK cells was found for CXCR1, we compared their relative chemotactic capacity toward a gradient of the CXCR1 ligand IL-8, a known chemoattractant for NK cells (36, 37) . Highly pure fluorescence-activated cell sorted CD56 dim Siglec-9 + and CD56 dim Siglec-9 -NK cells were stimulated to migrate to a gradient of 1 nM recombinant human IL-8 (rhIL-8). Concordantly with the higher CXCR1 expression, CD56 dim Siglec-9 + NK cells exhibited a significantly higher propensity for chemotaxis toward IL-8 ( Figure 5D ).
CD56 dim Siglec-9 + NK cells are reduced in peripheral blood of cancer patients. Given the peculiar characteristics of the CD56 dim Siglec-9 + NK cell subset and the well-established role of NK cells in antitumor immune responses (9), we next determined whether NK cells isolated from peripheral blood from cancer patients display altered occurrence of NK cell subsets or expression levels of Siglec-7 and -9 receptors. Compared with healthy donors (n = 22), absolute numbers of total NK cells among PBLs were similar in patients with colon adenocarcinoma (CoACA; n = 10) or malignant melanoma (n = 11) (Supplemental Figure 10A ). Furthermore, no difference in terms of the cytolytic capacity of NK cells was observed between NK cells from melanoma patients and healthy donors (Supplemental Figure 10B ). For flow cytometric analysis of Siglec-7 and -9, NK cells were analyzed with or without neuraminidase pretreatment to exclude masking effects by bound sialoglycan ligands. Siglec-7 was expressed at similar levels on peripheral blood NK cells of cancer patients and healthy donors (Supplemental Figure 10C ). Interestingly, both positivity and expression levels of Siglec-9 among peripheral blood CD56 dim NK cells were significantly reduced in the malignant melanoma and CoACA patients compared with healthy donor controls ( Figure 6, A and B) . Neuraminidase treatment enhanced the staining, which suggests that Siglec-9 receptors are partially masked by bound sialoglycans. However, Siglec-9 staining after unmasking by enzymatic treatment remained lower in NK cells of cancer patients, which confirmed that the expression of this surface receptor is reduced in cancer. The reduced occurrence of CD56 dim Siglec-9 + NK cells in peripheral blood of cancer patients might eventually be associated with the enhanced chemotactic properties of this subset (migration), but is likely attributable to other, yet-unknown factors, including cell-specific characteristics.
Discussion
Altered surface glycosylation with overexpression of sialoglycans that engage inhibitory Siglec receptors on NK cells may provide a general mechanism to shield tumor cells from innate immunity. By this strategy, tumor cells might counter NK cell activation, after loss of MHC class I expression (missing-self) and disengagement of classical inhibitory NK receptors, by interacting with alternative ITIM-containing -but MHC-independent -Siglec receptors. Our present findings revealed that sialic acid-containing ligands of the human inhibitory NK cell receptors Siglec-7 and -9 were widely expressed on tumor cells of different histological origin. Expression of Siglec-7 and -9 ligands protected malignant cells from attack by NK cells in vitro and in an in vivo model, using mice with a reconstituted human NK cell compartment. Interference with Siglec-ligand interactions conferred substantially increased NK cell cytotoxicity, not only against NK cell-susceptible K562 tumor cells, but also against NK cell-resistant cells. Depending on their differential expression on tumor cells, Siglec ligands might preferentially interact with the pan-NK cell receptor Siglec-7 or with Siglec-9, which was expressed on a mature subset of cytotoxic CD56 dim NK cells with enhanced chemotactic potential. This CD56 dim Siglec-9 + NK cell subset was found to be reduced in the peripheral blood of cancer patients.
The importance of directly studying the sialome on the intact cell or tissue, taking into account the spatial and complex cellular organization of sialic acid, has recently been highlighted (29) . Therefore, we directly probed tumor cells and tissue sections for detection of Siglec ligands using recombinant soluble chimeras of Siglec molecules fused with the Fc portion of human IgG1. Such pseudoantibodies have been suggested to be powerful tools for detecting specific types and arrangements of sialic acids in situ (1) . Given the broad Siglec-7 and -9 binding to different tumor types, it is conceivable that future pulldown assays using Siglec-Fc fusion proteins might lead to the identification of further physiological or pathophysiological Siglec ligands and, importantly, of novel tumor markers and tumor-specific targets for therapy. Candidate ligands are tumor-related mucins that contain predominantly Ser-or Thr-linked (O-linked) oligosaccharides, including sialoconjugate tumor antigens (e.g., STN). Indeed, MUC16 has recently been identified as a ligand for Siglec-9 (20) . Cell surface MUC16 is overexpressed by human epithelial ovarian tumors, and shed MUC16 can be detected in peritoneal fluid or serum as the tumor marker CA125. Other candidate ligands are gangliosides, which are known to be highly expressed in a broad variety of tumor types (2) and have been reported to be specifically bound by Siglec-7 and -9 (38, 39) . Notably, the gangliosides GD3, GD2, and GT1b are found predominantly on human tissue and tumor cells of neuroectodermal origin and constitute ligands for Siglec-7 and -9, which in our analysis exhibited strong binding to melanoma cell lines or melanoma lesions in situ as well as to primary leukemic cells of patients with AML or CLL. Enhanced expression of the ganglioside GD3 in GD3 synthase-transfected P815 cells strongly bound to recombinant Siglec-7-Fc protein, but caused enhancement (rather than inhibition) of NK cell cytotoxicity, due to Siglec-7-independent effects (10) . The ganglioside DSGb5 was reported to be expressed on renal carcinoma cells and to serve as a ligand for Siglec-7 (27) . GD3 or DSGb5 expression alone had no effect on untreated NK cells, and pretreatment of NK cells with neuraminidase was required to inhibit NK cell cytotoxicity, probably by unmasking Siglec-7 (10, 27) . In contrast to these reports, we showed here that unmodified expression of Siglec-7 or -9 ligands on malignant cells of distinct types of cancer was strong enough to directly inhibit antitumor responses of human primary NK cells. Hence, multiple heterogenous putative ligands for Siglec-7 and -9 exist, and quantitative and qualitative differences in distinct tumor types appear to determine their protective capacity against NK cell-mediated immune responses.
To date, no detailed phenotypical analysis comparing CD56 dim Siglec-9 + and CD56 dim Siglec-9 -NK cells has been performed. Hence, the abundant expression of Siglec-9 ligands on tumor cells prompted us to phenotypically and functionally analyze this NK cell subset. We found that CD56 dim Siglec-9 + NK cells exhibited a more mature phenotype, with higher expression levels of inhibitory KIRs and ILT2 receptors and concomitantly reduced -but still preserved -cytotoxic capacity to kill K562 target cells. In contrast, the chemotactic potential of CD56 dim Siglec-9 + NK cells to migrate toward IL-8 was superior to that of CD56 dim Siglec-9 -NK cells, and surface expression levels of the chemokine receptors CXCR1 (IL-8 receptor) and CX3CR1 was higher on this subset. Based on telomere length, CD56 dim NK cells had undergone approximately 5-10 more cell divisions than CD56 bright NK cells, assuming an average telomere shortening of 50-100 bp per cell division (40) . Interestingly, we found no difference in telomere length between the CD56 dim Siglec-9 + and CD56 dim Siglec-9 -NK cell subsets, despite the observed phenotypically fully mature state of peripheral blood CD56 dim Siglec-9 + NK cells. These findings are indicative of a proliferation-independent role of Siglec-9 as a maturation marker. The frequency of CD56 dim Siglec-9 + NK cells was higher in cord blood compared with adult peripheral blood, and neuraminidase treatment demonstrated that CD56 dim Siglec-9 + NK cells comprised even the majority of cord blood CD56 dim NK cells. These data suggest that acquisition of Siglec-9 is an early event upon differentiation from CD56 bright to CD56 dim NK cells, but expression of the receptor might be transient and only stabilized in cells that undergo full maturation, while being lost in activated short-lived NK cells. It has been proposed that immunological parameters in cancer could be used as a prognostic factor (41) . Indeed, immunological scores have been reported as a better predictor of patient survival than contemporary histopathological methods used to stage colorectal cancer (42) . In this regard, our observation that the frequency of CD56 dim Siglec-9 + NK cells and Siglec-9 expression levels were reduced in the peripheral blood of malignant melanoma and CoACA patients warrants future clinical studies. Detailed analysis of patient samples at different stages of disease might test the suitability of Siglec-9 expression as a biomarker and provide explanations for the decreased occurrence of CD56 dim Siglec-9 + NK cells in cancer.
Our findings indicate that targeting Siglec-7 and -9 on NK cells, or their ligands on malignant cells, might prove an attractive strategy by which to broaden indications or to implement current strategies for NK cell-based therapy to augment antitumor immunity (43) . The observation that NK cells were able to overcome the resistance of presumably NK cell-nonsusceptible tumor cells suggests that this approach may expand the range of indications for NK cell-based strategies. Manipulation of inhibitory receptors has been recently exploited in the context of both innate (e.g., NK cells) and adaptive (e.g., CD8 + T cells) immunity to enhance antitumor activity. In both preclinical models and clinical trials of cancer patients, blockade of KIRs as well as interference with CTLA-4 or PD-1 provided solid in vivo evidence that modulation of the balance between inhibitory and activating signals in both adaptive and innate immune cells might represent an attractive strategy for combating hematologic malignancies as well as solid tumors (43) (44) (45) (46) (47) . Similarly, it might be speculated that the clinical efficacy of allogeneic KIR-mismatched human stem cell transplants in the clinical setting of leukemic diseases might be further enhanced by blockade of Siglec-7 and -9 on donor NK cells (48) . Inversely, agonistic triggering of Siglec-7 and -9 as inhibitory NK cell receptors might prove promising in the context of reducing graft failure in certain types of solid organ transplantation (49) . The cell type-restricted,
Figure 6
The CD56 dim Siglec-9 + NK cell subset is reduced in the peripheral blood of cancer patients. (A and B) Expression of Siglec-9 on peripheral blood NK cells of healthy donors (n = 22) or patients with melanoma (n = 11) or CoACA (n = 10). Shown are frequency (A) and GMFI ratio of specific staining to isotype-matched control (B), with or without neuraminidase treatment. Lines within boxes denote 50th percentile; upper and lower margins of the boxes denote 25th and 75th percentile; whiskers denote 5th and 95th percentile. *P < 0.05, **P < 0.005, ***P < 0.001, Student's t test.
(Dako) and visualized with Liquid DAB+ Substrate Chromogen System (Dako). All tissue sections were counterstained with hematoxylin. For morphologic analysis, an Axiovert 35 microscope (Carl Zeiss) was used.
Mice. NSG (NOD/LtSz-SCID IL-2Rγ null ) mice were obtained from the Jackson Laboratory and maintained at the Institute of Experimental Immunology of University of Zurich under specific pathogen-free conditions. Newborn NSG mice were irradiated with 100 cGy using a Cs source. 5-6 hours after irradiation, mice were injected intrahepatically with 1 × 10 5 CD34 + human hematopoietic progenitor cells derived from human fetal liver tissue (obtained from Advanced Bioscience Resources). Preparation of human fetal liver tissue and isolation of human CD34 + cells was done as described previously (32, 54) . Reconstitution of human immune system components in mice (i.e., huNSG mice) was analyzed 10-12 weeks after engraftment and again before the start of experiments. Animals used in experiments were 4-5 month of age.
In vivo killing assay. K562 and HeLa target cells were labeled with 2 μM of the red fluorescent dye PKH26 (Sigma-Aldrich) according to the manufacturer's protocol and extensively washed. Half of PKH26-labeled cells were then treated with 50 mU neuraminidase (Roche Diagnostics) in RPMI plus 0.5% FCS for 30 minutes at 37°C; the other half were left untreated. After incubation with neuraminidase, target cells were stained with 1 μM CFSE (Molecular Probes), whereas untreated cells were labeled with 5 μM CFSE. In each case, cell populations were washed, and 1-2 × 10 6 cells per population were injected i.p. into huNSG mice pretreated with 50 μg poly I:C (Invivogen) for 12 hours, as previously described (4) . Cells were harvested after 12 hours by peritoneal lavage, pelleted, washed, and stained with antibodies against murine CD45 (Biolegend) and human NKp46 (BD Biosciences) for 30 minutes on ice. Acquisition of flow cytometric data was performed on a LSR Fortessa cytometer (BD Biosciences).
Statistics. Unless otherwise indicated, data represent mean ± SEM. Significance of the results was determined using 2-tailed Student's t test. A P values less than 0.05 was considered significant.
Study approval. All human studies were in accordance with the guidelines of -and approved by the cantonal ethical committees of -Bern, Lausanne, and Zurich, Switzerland. Written informed consent was received from participants prior to inclusion in the study. All animal protocols were approved by the cantonal veterinary office of the canton of Zurich, Switzerland (protocol nos. 116/2008 and 148/2011).
